A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer

Gynecologic Oncology

Volumn 90, Issue 1, 2003, Pages 64-69

  McMeekin, D Scott ^a,i   Gordon, Alan ^b   Fowler, Jeffrey ^c   Melemed, Allen ^d   Buller, Richard ^e   Burke, Thomas ^f   Bloss, Jeffery ^d,g   Sabbatini, Paul ^h  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b TEXAS ONCOLOGY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g UNIVERSITY OF MISSOURI   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARZOXIFENE; DRUG METABOLITE; GESTAGEN; NORARZOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG; PIPERIDINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; CALCULATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRY SKIN; EDEMA; ENDOMETRIUM CARCINOMA; FEMALE; GANGRENE; HOT FLUSH; HUMAN; KAPLAN MEIER METHOD; MULTICENTER STUDY; MYALGIA; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PIGMENT DISORDER; PRIORITY JOURNAL; RECURRENT CANCER; SALVAGE THERAPY; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR RECURRENCE; VOMITING; WEIGHT REDUCTION; BLOOD; DISEASE FREE SURVIVAL; ENDOMETRIUM TUMOR; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PIPERIDINES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THIOPHENES;

EID: 0037824471     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00203-8     Document Type: Article

References (25)

1. Greenlee R., Murray T., Bolden S., Wingo P. Cancer statistics, 2000. CA Cancer J Clin. 50:2000;7-33.
2. Podratz K.C., O'Brien P.C., Malkasian G.D., Decker D.G., Jefferies J.A., Edmonson J.H. Effects of progestational agents in treatment of endometrial carcinoma. Obstet and Gynecol. 66:1985;106-110.
3. Thigpen T., Blessing J., Disaia P. Oral medroxyprogesterone acetate in advanced or recurrent endometrial cancer results of therapy and correlation with estrogen and progesterone receptor levels: the Gynecologic Oncology Group experience . Baulier E., Iacobelli S., McGuire W. Endocrinology and malignancy. 1986;446-454 Parthenon, Pearl River, NY.
4. Lentz S.S., Brady M.F., Major F.J., Reid G.C., Soper J.T. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma a gynecologic Oncology Group study . J Clin Oncol. 14:1996;357-361.
5. Thigpen J.T., Brady M.F., Alvarez R.D., Adelson M.D., Homesley H.D., Manetta A., et al. Oral medroxy progesterone acetate in the treatment of advanced or recurrent endometrial cancer a dose-response study by the Gynecologic Oncology Group . J Clin Oncol. 17:1999;1736-1744.
6. Thigpen J.T., Buchsbaum H.J., Mangan C., Blessing J.A. Phase II trial of Adriamycin in the treatment of advanced or recurrent endometrial carcinoma a Gynecologic Oncology Group study . Cancer Treat Rep. 63:1979;21-27.
7. Ball H.G., Blessing J.A., Lentz S.S., Mutch D.G. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium a Gynecologic Oncology Group study . Gynecol Oncol. 62:1996;278-281.
8. Barrett R.J., Blessing J.A., Homesley H.D., Twiggs L., Webster K.D. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma a phase II study of the Gynecologic Oncology Group . Am J Clin Oncol. 16:1993;494-496.
9. Kelley RM. In: Proceedings of the Second Conference on Steroids and Cancer. Chicago: American Medical Association, 1951, p. 116.
10. Buzdar A., Enas N., Melemed A., Dhingra K., Seidman A., Munster P.N., et al. Phase I study of a third-generation selective estrogen receptor modulator, LY353381 HCl in metastatic breast cancer. J Clin Oncol. 19:2001;2002-2009.
11. Kaplan E.L., Meier P. Nonparametric estimation of incomplete observations. J Am Statist Assoc. 53:1958;457-481.
12. Leemis L.M., Trivedi K.S. A comparison of approximate interval estimators for the Bernouilli parameter. Am Stat. 50:1996;63-68.
13. Kauppila A. Progestagen therapy of endometrial, breast and ovarian carcinoma. Acta Obstet Gynecol Scand. 63:1984;441-450.
14. Moore T.D., Phillips P.H., Nerenstone S.R., Cheson B.D. Systemic treatment of advanced and recurrent endometrial carcinoma current status and future directions . J Clin Oncol. 9:1991;1071-1088.
15. Parazzini F., La Vecchia C., Bocciolone L., Franceschi S. The epidemiology of endometrial cancer. Gynecol Oncol. 41:1991;1-16.
16. Benraad T.J., Friberg L.G., Koenders A.J.M., Kullander S. Do estrogen and progesterone receptors (E2R and PR) in metastasizing endometrial cancers predict the response to gestagen therapy? Acta Obstet Gynecol Scand. 59:1980;155-159.
17. Martin P.M., Rolland P.H., Gammerre M., Serment H., Toga M. Estradiol and progesterone receptors in normal and neoplastic endometrium correlations between receptors, histopathological examinations and clinical responses under progestagen therapy . Int J Cancer. 23:1979;321-329.
18. Creasman W.T., Soper J.T., McCarty K.S. Jr, McCarty K.S. Sr, Hinshaw W., Clarke-Pearson D.L. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol. 151:1985;922-932.
19. Fiorica J., Brunetto V., Hanjani P., Lentz S., Mannel R., Anderson W. A phase II study of recurrent and advanced endometrial carcinoma treated with alternating courses of megestrol acetate and tamoxifen citrate. Proc Am Soc Clin Oncol. 19:2000;1499. Abstract.
20. Thigpen T., Brady M.F., Homesley H.D., Soper J.T., Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma a Gynecologic Oncology Group study . J Clin Oncol. 19:2001;364-367.
21. Carlson J.A., Allegra J.C., Day T.G., Wittliff J.L. Tamoxifen and endometrial carcinoma alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia . Am J Obstet Gynecol. 149:1984;149-153.
22. Kline R.C., Freedman R.S., Jones L.A., Atkinson E.N. Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate. Cancer Treat Rep. 71:1987;327-328.
23. Schinella R.A., Davis T.E., Weiner L.M., Pandya K.J., Yeap B.Y., Krook J.E., Erban J.K. Megestrol and tamoxifen in patients with advanced endometrial cancer an Eastern Cooperative Oncology Group study (E4882) . Am J Clin Oncol. 24:2001;43-46.
24. Thigpen J.T., Blessing J.A., Homesley H., Creasman W.T., Sutton G. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma a Gynecologic Oncology Group study . Gynecol Oncol. 33:1989;68-70.
25. Klijn J., den Hoed Kliniek D. Multicenter phase II study of selective estrogen response modulator (SERM) LY353381 in advanced or recurrent endometrial cancer objective responses in progestagen sensitive patients . Proc Am Soc Clin Oncol. 19:2000;386a. (Abstract 1527).